Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.

@article{Mwafongo2014RenalEA,
  title={Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.},
  author={Albert Mwafongo and Kondwani Nkanaunena and Yu Zheng and Evelyn Hogg and Wadzanai P Samaneka and Lloyd B. Mulenga and Abraham M. Siika and Judith C Currier and Shahin Lockman and Michael R. Hughes and Mina C Hosseinipour},
  journal={AIDS},
  year={2014},
  volume={28 8},
  pages={1135-42}
}
OBJECTIVES Tenofovir disoproxil fumarate (TDF) has been associated with renal insufficiency. Co-administration with boosted protease inhibitors, which increases its exposure, may further increase the risk of renal insufficiency. METHODS We compared the incidence of renal events among women taking TDF co-administered with lopinavir/ritonavir (LPV/r) versus those co-administering TDF with nevirapine (NVP). Renal events were defined as a confirmed drop in creatinine clearance associated with a… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS